For decades, the luxury skincare industry operated as a high-margin consumer category—a commoditized market built on aesthetic masking. That era has concluded. We are currently witnessing a decisive migration of R&D capital into a new domain: Cellular Longevity. This is not a shift in marketing; it is a fundamental re-engineering of the industry's value chain, moving from cosmetic maintenance to high-barrier biological intervention.
The market has bifurcated. On one side,
